WRBC
STLN

W.R. Berkley Corp’s Starling Oncology STLN Stock Holding History

W.R. Berkley Corp’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-49,060
Closed -$488K – 584
2021
Q3 		$488K Buy
49,060
+24,212
+97% +$240K 0.03% 340
2021
Q2 		$247K Hold
24,848
– – 0.02% 307
2021
Q1 		$247K Buy
+24,848
New +$265K 0.03% 267

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

W.R. Berkley Corp's STLN Position: Q4 2021 in Review

W.R. Berkley Corp sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 49,060 shares — an estimated $488K sold.

W.R. Berkley Corp first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $488K in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • W.R. Berkley Corp reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • W.R. Berkley Corp sold 49,060 Starling Oncology shares in Q4 2021, an estimated $488K.
  • W.R. Berkley Corp first reported a position in Starling Oncology in Q1 2021 and held it in 3 quarters.
  • W.R. Berkley Corp's Starling Oncology position peaked at $488K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on W.R. Berkley Corp's 13F filing for Q4 2021, filed 14 Feb 2022.